Our flagship test, Canine CGP (Comprehensive Genomic Profiling), is the world’s largest, most advanced tumor genomic diagnostic test available for dogs with cancer. Using whole exome sequencing, Canine CGP evaluates all major mutation types across 20,257 coding genes in the canine genome, providing the most comprehensive view of tumor biology to date to support personalized cancer management and effective treatment.
For comparison, existing commercial tests such as Vidium (~120 genes) and FidoCure (~67 genes) cover only a small fraction of the genome, while other emerging tests assess only a few hundred genes. This difference in genomic coverage translates directly into clinical value with Canine CGP offering:
- Higher clinical yield and fewer “empty” results
- More treatment options, spanning all targeted therapy, immunotherapy, selected chemotherapy, and radiation
- Pharmacogenomic insights (e.g., MDR1 for chemotherapy sensitivity)
- Improved diagnosis and prognosis insights
- Unparalleled understanding into tumor genome and biology of each tumor
Clinical Performance of Canine CGP
Clinical Performance to date: >300 cases analyzed across 70+ cancer types (as of Oct 2025)
- Quality excellence: No case has failed to generate a report. One case required a 2nd sampling, and 19 cases required a 2nd workflow attempt, all successfully resolved.
- Therapeutic actionability (99.7%): In every case but one, we identified putative pathogenic mutations and clinical actionable biomarkers to support treatment planning. The one negative case was a benign leiomyoma.
- Diagnostic value: In over one-third of cases, Canine CGP provided critical diagnostic clarity in challenging scenarios, with diagnostic utility expected to increase as our dataset continues to grow.
Explore these resources to learn how Canine CGP insights translate into clinical practice.